LOAME
NBIX icon

Lombard Odier Asset Management (Europe)’s Neurocrine Biosciences NBIX Stock Holding History

Lombard Odier Asset Management (Europe)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,000
Closed -$2.43M – 165
2025
Q1 		$2.43M Hold
22,000
– – 0.2% 115
2024
Q4 		$3M Buy
+22,000
New +$2.72M 0.19% 136

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lombard Odier Asset Management (Europe)'s NBIX Position: Q2 2025 in Review

Lombard Odier Asset Management (Europe) sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 22,000 shares — an estimated $2.43M sold.

Lombard Odier Asset Management (Europe) first reported a position in NBIX in Q4 2024 and held it in 2 quarters. The position peaked at $3M in Q4 2024. 586 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Lombard Odier Asset Management (Europe) reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • Lombard Odier Asset Management (Europe) sold 22,000 Neurocrine Biosciences shares in Q2 2025, an estimated $2.43M.
  • Lombard Odier Asset Management (Europe) first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 2 quarters.
  • Lombard Odier Asset Management (Europe)'s Neurocrine Biosciences position peaked at $3M in Q4 2024.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Lombard Odier Asset Management (Europe)'s 13F filing for Q2 2025, filed 14 Aug 2025.